---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-093353"
form_type: "8-K"
ticker: "ALMS"
cik: "0001847367"
company_name: "ALUMIS INC."
filed_at: "2026-08-10T20:06:06+00:00"
generated_at: "2026-08-10T20:07:13.994869+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Envudeucitinib achieves 54% PASI 100 at 48 weeks; NDA on track for 4Q 2026

## Summary
- 54% of patients achieved PASI 100 (complete skin clearance) at 48 weeks; 75% achieved PASI 90.
- Integrated analysis (890 pts) showed 66% PASI 90 and 47% PASI 100 at 48 weeks.
- 1,509 patients rolled into ONWARD3 from ONWARD1/2 (>85% rollover); safety consistent, no new signals.
- NDA submission to FDA planned for 4Q 2026; LUMUS Phase 2b SLE topline expected 3Q 2026.

## SEC filing metadata
- accession: 0001104659-26-093353
- form_type: 8-K
- ticker: ALMS
- cik: 0001847367
- company_name: ALUMIS INC.
- filed_at: 2026-08-10T20:06:06+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/0001104659-26-093353-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-093353
- JSON: https://secwatch.observer/filing/0001104659-26-093353.json
- Plain text: https://secwatch.observer/filing/0001104659-26-093353.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.